Coronavirus: Booster dose of Pfizer-BioNTech vaccine 95.6% effective against symptomatic infections

The study is based on trials conducted on more than 10,000 people above 16 years of age.

Related Keywords

Germany ,United States ,German ,Albert Bourla ,Ugur Sahin ,Pfizer ,Drug Administration ,Pfizer Chief Executive Officer Albert Bourla ,Chief Executive Officer Ugur Sahin ,United States Based ,